Article Text

Download PDFPDF
Rare disease
Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue
  1. Erwin Woff1,
  2. Camilo Garcia1,
  3. Laure Tant2,
  4. Kristoff Muylle1,
  5. Ghanem Ghanem3,
  6. Pierre Bourgeois1,
  7. Patrick Flamen1
  1. 1Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  2. 2Department of Rheumatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
  3. 3Department of Radiopharmacy, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  1. Correspondence to Camilo Garcia, camilo.garcia{at}bordet.be

Summary

A 51-year-old man presented with generalised bone pain. Initial evaluation revealed a low serum phosphorus level and elevated urinary phosphorus excretion. Aminoaciduria was normal. Standard imaging showed only minimal changes. The patient was treated with daily oral supplementation with phosphate (1 g/day) and 1,25-dihydroxyvitamin D3 (1 μg/day) to maintain euphosphataemia. In spite of the fact that this treatment was maintained for 3 years, there was no modification of renal phosphate clearance. A diagnosis of hypophosphataemic osteomalacia with renal phosphate wasting was proposed. Therefore, tumour-induced osteomalacia was suspected, triggering a diagnostic workup to find the primary tumour. These tumours are known to express somatostatin receptors, so whole body positron emission tomography (CT) imaging was performed after intravenous administration of 68Ga-DOTA-TOC (68Ga-DOTA-D-Phe1-Tyr3-pentreotide). A solitary intense hot spot was detected in soft tissue near the right femoral internal condyle. Based on this result, curative resection of the tumour was performed.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.